In this retrospective cohort study, we explored the UK General Practice Research database (GPRD) to determine the hazard ratio of diabetes mellitus (DM) for patients prescribed antipsychotics compared with the GPRD general patient population in the UK. METHODS: An antipsychotic cohort comprised of patients exposed to both conventional and atypical antipsychotics (N = 46,111), individual antipsychotic cohorts comprised of patients exposed to a single antipsychotic, and a general patient population cohort (N = 266,272) derived from the GPRD database were studied. A Cox proportional hazard regression model was used to determine the hazard ratio (HR) of diabetes development between these cohorts. The covariates included in the model were age, gender, and the presence or absence of obesity. RESULTS: Compared to the GPRD general patient population cohort, patients exposed to antipsychotics had a higher risk of developing diabetes (HR = 1.5; CI = 1.1-1.9). The risk of developing diabetes during exposure to thioridazine and risperidone was significantly higher than that of the GPRD general patient population. Assessment of other antipsychotics was limited by sample size of the cohorts. CONCLUSIONS: Patients exposed to antipsychotic drugs have an increased risk of developing diabetes. It remains unclear to what extent the increased risk of diabetes is related to treatment factors or factors related to the underlying psychiatric conditions commonly treated with antipsychotic drugs.
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IMPROVEMENTS IN LIFE EXPECTANCY WITH LIFESTYLE CHANGES OR METFORMIN IN OVERWEIGHT, GLUCOSE INTOLERANT PATIENTS: A MODELING STUDY OF THE LONG-TERM IMPLICATIONS OF THE DIABETES PREVENTION PROGRAM
Palmer AJ 1 , Roze S 1 CORE Center for Outcomes Research, Basel, BS, Switzerland OBJECTIVES: The Diabetes Prevention Program (DPP) investigated the effects of intensive lifestyle changes (LsC) or metformin (MET) on delaying the onset of type 2 diabetes in overweight patients with impaired glucose tolerance (IGT). Patients randomized to either LsC or MET 850 mg twice daily reduced their risk of developing type 2 diabetes by 58% and 31% respectively, compared to controls. A simulation model was developed to explore the long-term implications of delaying onset of type 2 diabetes with LsC or MET. METHODS: A Markov model combined data from DPP with published data on mortality of IGT patients compared to type 2 diabetes, in order to calculate the possible long-term effects of delaying the onset of diabetes with LsC or MET on life expectancy (LE). The model simulated 3 states. "IGT", "type 2 diabetes", and "dead". Annual transition probabilities for each treatment arm were derived from the DPP, population studies, and national mortality statistics. LE was calculated for each treatment arm. Different assumptions were tested regarding the post-trial effect of the delay of onset of diabetes. Additional sensitivity analysis was performed to identify other parameters with important impacts on LE. RESULTS: Using the conservative assumption, LE from baseline age of 51 years was 22.95, 23.12, and 23.03 years for the control, LsC, and MET groups respectively. Using the optimistic assumption, LE further improved by 0.39 and 0.14 years for the LsC and MET groups respectively. Other parameters with important impacts on LE were the mortality rates in the states of "IGT" and "type 2 diabetes". CONCLUSIONS: Interventions that delay the onset of type 2 diabetes in overweight IGT patients may lead to important improvements in LE.
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OUTCOMES WITH ROSIGLITAZONE IN CLINICAL PRACTICE
McGibbon A 1 , Tuttle J 1 , Kim T 2 , Ur E 1 1 Dalhousie University, Halifax, NS, Canada; 2 GlaxoSmithKline, Mississauga, ON, Canada OBJECTIVES: Unlike older agents, rosiglitazone lowers blood glucose levels by directly acting on insulin resistance, the primary metabolic defect of type 2 diabetes, and has other positive metabolic effects on lipids and blood pressure. Outcomes of patients on rosiglitazone used as combination and monotherapy in routine Canadian clinical practice is reported. METHODS: Five Canadian centers participated in retrospective data collection. Charts were reviewed for over 635 patients on rosiglitazone with the use of a software program designed to track outcomes pre and post Avandia treatment such as glycemic control, metabolic parameters (including renal function, liver enzymes, and lipids) as well as weight, blood pressure and changes in diabetic medications. Patient data were entered into the software and analyzed using standard statistical methodology. RESULTS: In the analysis of 337 patients on rosiglitazone, the average age was 71.6 years with 44% females. Rosiglitazone was started as additional therapy to sulphonylureas (38%) or metformin (42%) or both (33.5%). There were 150 patients on rosiglitazone as monotherapy (44%). The relative reduction in HbA1c was 15.3% at
